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Local Expression of Indoleamine 2,3-Dioxygenase
Protects Engraftment of Xenogeneic Skin Substitute
Yunyuan Li1, Edward E. Tredget1, Abdi Ghaffari1, Xiaoyue Lin1, Ruhangiz T. Kilani1 and Aziz Ghahary1
The expression of indoleamine 2,3-dioxygenase (IDO), which metabolizes tryptophan, an essential amino acid,
into kynurenine, has been identified as having a key role in the prevention of the immune rejection of the semi-
allogeneic fetus during pregnancy. We have previously demonstrated that IDO expressed in fibroblasts causes
bystander CD4þ T cell damage as well as THP-1 cell damage by apoptosis. As T cells are primarily responsible for
graft rejection, here, we asked the question of whether engraftment of IDO-expressing xenogeneic fibroblasts
populated in a collagen matrix can be immuno-protected in an animal model. The results show a significant
reduction in the number of infiltrated CD3þ T lymphocytes on days 14 and 28 post-transplantation in the
wounds receiving IDO-expressing fibroblasts relative to controls. IDO-expressing human fibroblasts embedded
in bovine collagen on wounds in a rat model accelerates wound healing by promoting neovascularization
during the early stages and providing protection of the xenograft fibroblasts. Using a co-culture system, we
further confirm that IDO can induce angiogenesis through the depletion of tryptophan. These findings suggest
that IDO may have an application in promoting the engraftment of skin substitutes and other transplanted
organs.
Journal of Investigative Dermatology (2006) 126, 128–136. doi:10.1038/sj.jid.5700022
INTRODUCTION
The need for alternative, immediate, and permanent wound
closure materials has promised potential applications for the
treatment of cutaneous wounds. One approach postulated by
our research group is to generate a functional skin equivalent
with a local immunosuppressive factor such as indoleamine
2,3-dioxygenase (IDO) incorporated to genetically modify
either allo- or xenogeneic skin cells (Li et al., 2004b). IDO is
a rate-limiting enzyme that converts tryptophan to N-formyl-
kynurenine (Taylor and Feng, 1991). This unstable product is
further catabolized to kynurenine. It has been suggested that
IDO plays a key role in the prevention of the immune
rejection of the semi-allogeneic fetus (Munn et al., 1998) and
in the immune resistance of tumors (Uyttenhove et al., 2003).
In a co-culture system, we have recently demonstrated that
depletion of tryptophan by IDO jeopardizes the survival of
CD4þ lymphocytes and THP-1 monocytes (Li et al., 2004b).
We also found that IDO expression downregulates major
histocompatibility complex (MHC) class I levels on the
surface of IDO-expressing keratinocytes (Li et al., 2004a).
Based on this information, we hypothesize that skin cells
genetically modified with an IDO gene would be non-
rejectable.
In addition to host immune cell rejection as well as
cytokines and growth factors released in response to
engraftment, neovascularization also plays a critical role in
graft survival. It is well known that when vascularization at
the transplantation site is formed, several trophic factors
important in graft take are released, and grafted cells survive
(Boyce et al., 1995). Re-vascularization is characterized by
the development of new capillaries from pre-existing vessels
and requires endothelial cell proliferation, migration, and
differentiation in tubular arrays (Yoshida et al., 1996). A
number of growth factors (Davison and Benn, 1996),
extracellular matrix molecules (Sengar, 1996), enzymes
(Lorimier et al., 1996), and cell types (Schaffer and Nanney,
1996) are involved in this complex process. Re-vasculariza-
tion is vital and highly regulated during a variety of normal
physiological conditions, including ovulation, embryonic
development, and wound healing (Rissau, 1997). As IDO
catalyzes the degradation of tryptophan that causes bystander
immune cell damage, we then asked the question of whether
the expression of IDO would damage or delay re-vascular-
ization at the transplantation site.
Thus, the aim of this study was to evaluate the effects of
local IDO expression on xenogeneic graft take as well as
neovacularization formation in an in vivo rat model. The
results showed that engraftment of genetically modified IDO
xenogeneic fibroblasts embedded in a collagen matrix
accelerates wound healing in the rat model. Furthermore,
we demonstrated that IDO promotes angiogenesis in vivo
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and in vitro, and IDO can protect grafted cells from host
immune rejection.
RESULTS
Engraftment of IDO genetically modified human fibroblasts
embedded in collagen matrix accelerates healing of cutaneous
wounds
Prior to any in vivo experiments, the rate of IDO adenoviral
infection and IDO activity were evaluated. The infection
efficiency of adenovirus in fibroblasts and IDO activity in the
conditioned medium were then determined. As described in
the previous study (Li et al., 2004b), about 30% of fibroblasts
were infected (data not shown). As shown in Figure 1a, the
kynurenine levels in IDO adenoviral-infected fibroblast
conditioned medium were significantly increased as com-
pared to either non-treated or empty vector-infected fibroblast
conditioned medium. To assess the effect of IDO on wound
healing, normal human fibroblasts, mock recombinant
adenovirus-infected human fibroblasts, or IDO recombinant
adenovirus-infected human fibroblasts, embedded in bovine
collagen gels, were applied onto 6 mm full-thickness wounds
generated in the dorsal skin of rats. The sizes of wounds that
received IDO adenovirus-infected fibroblasts were indistin-
guishable from those that received no treatment, uninfected
human fibroblasts, or mock recombinant adenovirus-infected
fibroblasts on day 4 (33.177.2 vs 42.9712 vs 3573.9 vs
43.977.7%, IDO vs non-treated versus fibroblasts versus
mock, P40.05) (Figure 1c). However, on day 8, all wounds
grafted with IDO adenovirus-infected fibroblasts were com-
pletely healed, while the other wounds remained open
(Figure 1b). As shown in Figure 1c, measurement of the
wounds that received engraftment of IDO adenovirus-infected
fibroblasts was significantly smaller compared to either
non-treated grafts with non-treated human fibroblasts or grafts
with mock recombinant adenovirus-infected human
fibroblasts (7.075.0 vs 18.475.2 vs 19.673.7 vs 25.37
4.9%, IDO vs non-treated versus fibroblasts versus mock,
Po0.01).
Examination of hematoxylin and eosin-stained wound
sections revealed a dramatic difference in thickness of the
epidermal layer between IDO collagen gels and all other
control wounds. More rapid re-epithelialization was ob-
served in wounds that received IDO adenovirus-infected
human fibroblasts (Figure 2d) compared to other groups on
day 8 post-transplantation; however, a marked delay in re-
epithelialization was seen in either engraftment of non-
treated human fibroblasts (Figure 2b) or engraftment of mock
recombinant adenovirus-infected human fibroblasts (Figure
2c) compared to non-treated wounds (Figure 2a). Granulation
tissue deposition was more abundant and the number of
infiltrated inflammatory cells was less in wounds that
received IDO-expressing fibroblasts as compared to other
groups (data not shown). In contrast, wounds that received
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Figure 1. Grafting IDO genetically modified human fibroblasts populated
collagen gels accelerates wound healing in rats. (a) Kynurenine levels in IDO-
transfected fibroblast conditioned medium. Fibroblasts were infected by
either Ad-GFP or Ad-GFP-IDO. Free viral particles were removed by washing
the cells with phosphate-buffered saline after 30 hours, and fresh medium was
added. Conditioned medium was collected from the same number of infected
and non-infected cells at 72 hours post-transfection. Kynurenine levels were
determined. (b) Photographic findings of wounds on day 8 post-transplanta-
tion. Wound closure analysis on days 4 and 8 (n¼ 6). (c) The effect of IDO-
expressing fibroblasts on wound healing was comparable to that of other
groups on days 4 and 8, respectively.
Figure 2. Hematoxylin and eosin staining of wound sections on day 8 for
untreated (a), uninfected fibroblasts (b), mock adenovirus-infected fibro-
blasts (c), and IDO adenovirus-infected fibroblasts (d) treated wounds. The
green arrows represent the wound edge, and the black arrows represent re-
epithelialization areas.
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either non-treated human fibroblasts or mock adenovirus-
infected human fibroblasts showed a significant decrease in
the amount of granulation tissue deposition and abundant
inflammatory cell infiltration as compared to non-treated
wounds (data not shown).
Efficacy of engrafting IDO genetically modified fibroblasts
embedded in collagen gels in preventing acute host rejection
There have been conflicting reports of the survival and
immune reaction of allografts of cultured skin cells,
especially fibroblasts (Sher et al., 1983; Hultman et al.,
1996; Erdag and Morgan, 2004). However, like other cell
types (Schmidt et al., 2003), xenogeneic fibroblasts have
been shown to stimulate a high degree of host immune
response (Isik et al., 2003; Erdag and Morgan, 2004;
Schneider et al., 2004). To assess whether IDO plays a role
in the prevention of grafted skin cells from host immune
rejection, in the present study, we performed a xenograft with
either non-treated, mock adenovirus-infected or IDO adeno-
virus-infected human fibroblasts in a rat model. Cells were
then traced by using GFP expression as a marker. The
immune response was evaluated by infiltrated CD3þ T
lymphocytes. As shown in Figure 3a and b, there were no
GFP-expressing cells within the wounds that received the
mock adenovirus-infected fibroblasts on days 8 and 28,
respectively. Similarly, we did not find GFP-positive cells in
the control wounds on day 14 (data not shown). However,
xenogeneic human fibroblasts expressing IDO survived and
were easily detectable within the reticular dermis as
indicated by GFP-positive staining on days 8 (Figure 3c), 14
(data not shown), and 28 (Figure 3d). These findings suggest
that IDO does protect xenografted human fibroblasts from
host immune rejection. Furthermore, as shown in Figure 3
and Table 1, there was no significant difference in the
number of infiltrated CD3þ T lymphocytes in wounds that
received IDO-expressing human fibroblasts compared to
either non-treated wounds, wounds that received uninfected
human fibroblasts, or mock adenovirus-infected human
fibroblasts on day 8; however, these differences become
significant on days 14 and 28. Wounds that received either
untreated human fibroblasts (Figure 4b, f) or mock adeno-
virus-infected fibroblasts (Figure 4c, g) showed massive
infiltrated lymphocytes and some clustered lymphocytes
distributed at the reticular dermis as compared to untreated
wounds on days 14 (Figure 4a) and 28 (Figure 4e). However,
wounds that received IDO adenovirus-infected human
fibroblasts revealed a few infiltrated CD3þ cells on days 14
(Figure 4d) and 28 (Figure 4d). This is a clear indication that
the local expression of IDO by genetically modified
xenogeneic fibroblasts suppresses the infiltration of T
lymphocytes at the wound site.
Increased neovascularization in wounds that received IDO
genetically modified fibroblasts embedded in collagen
Slow re-vascularization is thought to be a cause for the
rejection of allo- and xenogeneic engraftment (Boyce et al.,
1995). To further evaluate the effects of IDO on neovascular-
ization in vivo, we performed CD31 immunostaining on
wound sections obtained from untreated control (Figure 5a),
fibroblasts (Figure 5b), mock-infected (Figure 5c), and IDO
adenovirus-infected fibroblasts grafted wounds (Figure 5d).
The results showed a significant increase in the number of
capillary-like vessels in wounds that received IDO-expressing
fibroblasts compared to other groups on day 8. Data obtained
from six sections randomly selected from three wounds of
each group demonstrated a two- to three-fold increase in the
number of vessels per mm2 in wounds that received IDO-
expressing fibroblasts relative to those obtained from wounds
of either non-treated, those that received fibroblasts, or mock
adenovirus-infected fibroblasts (Figure 5e, Po0.01). We also
performed CD31 staining at later time points on another set of
Figure 3. Detection of grafted fibroblasts by GFP immunohistochemistry
staining. Sections of wounds that received either mock adenovirus-infected
fibroblasts (a) at day 8 post-transplantation and (b) at day 28 post-
transplantation, IDO adenovirus-infected fibroblasts (c) at days 8 and 28
(d) post-transplantation were prepared and GFP expression was detected
by immunostaining. Arrows show GFP-positive cells.
Table 1. Infiltrated CD3+ cell number per high-power
field at various times postgrafting
Day 8 Day 14 Day 28
Untreated wounds 23.2712.2 14.575.3 11.977.5
Untreated
fibroblasts
19.877.8 39.5727.71 25.8715.11
Mock adenovirus
fibroblasts
18.377.1 45.6715.62 23.4721.2
IDO adenovirus
fibroblasts
17.5711.2 1.671.63 5.775.13
1Po0.05.
2Po0.01 versus untreated wounds, respectively.
3Po0.01 versus wounds receiving either untreated fibroblasts or mock
adenovirus-infected fibroblasts.
n=10 high-power fields.
Data were expressed as the mean7SD.
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samples obtained from animals that received similar treat-
ment on days 14 and 28. The findings showed no significant
difference in microvascular density between wounds that
received IDO-expressing human fibroblasts and controls
(data not shown).
IDO expression promotes the formation of vessel-like structures
in vitro
To further investigate the impact of IDO expression on re-
vascularization, in a co-culture system, HUVECs and human
dermal fibroblasts with or without recombinant adenovirus
infection were mixed in a ratio of 1:1 in six-well plates. To
distinguish endothelial cells from fibroblasts in our co-culture
system, the living HUVECs were labeled with DiI prior to co-
culturing with fibroblasts. By inverted fluorescent microscopy,
the DiI fluorescent label (red color) and GFP expression (green
color) in recombinant adenovirus-infected fibroblasts allowed
us to identify different cell types. In this system, the DiI signal
was clearly detectable for up to 30 days.
The results showed that the DiI-labeled endothelial cell
cords were extended and elongated to form multicellular
capillaries when co-cultured with IDO-expressing fibroblasts
(Figure 6c) for a period of 20 days. However, these structures
were not seen when HUVECs were grown in the presence of
untreated fibroblasts (Figure 6a) or mock adenovirus-infected
fibroblasts (Figure 6b) for the same period. These findings
strongly support the results obtained from the in vivo
experiment described above, indicating that IDO can directly
initiate angiogenesis.
Depletion of tryptophan by IDO results in the formation of
capillary-like structures in vitro
To determine how vessel-like structures are formed in
response to the local expression of IDO, the formation of
these structures in response to tryptophan-degraded products
such as kynurenine and the depletion of tryptophan in a co-
culture system were evaluated. As shown in Figure 7, the
addition of kynurenine at a concentration of 50 mg (Figure 7b)
and 100 mg (Figure 7c) to the conditioned medium of co-
culture HUVECs with non-treated human fibroblasts had no
effect on the formation of capillary-like structure relative to
that of control (Figure 7a). However, under similar experi-
mental conditions, we found that the addition of L-tryptophan
at a concentration of 50 mg (Figure 7e) and 100mg (Figure 7f)
to the conditioned medium of co-culture HUVECs and IDO-
expressing fibroblasts markedly decreased DiI-labeled en-
dothelial cell extension, elongation, and branching as
compared to those without the addition of tryptophan (Figure
7d). These data suggest that the depletion of tryptophan is
probably the main reason by which capillary-like structures
are formed in response to IDO expression.
DISCUSSION
A number of recent studies suggest that IDO may play a key
role in local immunosuppression (Munn et al., 1998, 1999,
2004; Friberg et al., 2002; Uyttenhove et al. 2003; Hayashi
et al., 2004). In an attempt to develop a non-rejectable skin
substitute containing either allo- or xenogeneic skin cells, we
have conducted a series of experiments to test whether IDO
can function as a local immunosuppressive factor to protect
allo- or xenogeneic skin cell engraftment. In previous studies,
we have demonstrated that immune cells, but not primarily
fibroblasts, keratinocytes, and endothelial cells, are suscep-
tible to low tryptophan levels in the conditioned medium (Li
et al., 2004b). These findings, therefore, lead us to
hypothesize that IDO may function as a local immunosup-
pressive factor that protects allo- or xenogeneic engraftment
in an animal model. In this study, we found that wounds that
received IDO-expressing human fibroblasts healed faster
compared to controls (untreated wounds, wounds that
received untreated human fibroblasts, or mock adenovirus-
infected fibroblasts in an animal model). Further studies
found that at least two mechanisms might be accountable for
the promotion of healing in wounds treated with IDO-
expressing fibroblasts. First, the logical explanation would
Figure 4. Detection of CD3þ -infiltrated lymphocytes within xenografts.
Immunohistochemical staining of CD3þ lymphocytes in sections of untreated
wounds on days 14 (a) and 28 (e) as well as those wounds that received
untreated fibroblasts on days 14 (b) and 28 (f) are shown. Similarly,
immunostaining for CD31-expressing cells infiltrated within those wounds that
received mock adenovirus-infected fibroblasts on days 14 (c) and 28 (g) as well
as wounds that received IDO adenovirus-infected fibroblasts on days 14
(d) and 28 (h) are shown. The arrows show cluster distributions of infiltrated
CD3þ lymphocytes at the wound site.
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simply be that engrafted skin substitute remained intact due
to the protective role of IDO and this resulted in earlier
epithelialization, thus shortening the wound closure time.
Another mechanistic reason might be the one that we have
shown in this paper, indicating that IDO induces angiogen-
esis and this, at least in part, would promote the healing
process. The graft take that results from IDO expression was
supported by experiments showing the presence of GFP-
positive cells within the wound sites at all time points. This
finding was further confirmed by demonstrating a significant
decrease in the number of infiltrated CD3þ T lymphocytes 2
and 4 weeks post-transplantation. Additionally, we found that
IDO directly promotes neovascularization as demonstrated
in vivo and in vitro, which may in part be accounted for
by the more rapid healing. Depletion of tryptophan by IDO in
the local environment seems to contribute to the formation
of capillary-like structures, mainly because an addition
of tryptophan prevented endothelial cells forming these
structures.
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Figure 5. Detection and quantitative analysis of capillary-like structures in wound sections on day 8 post-transplantation. Either untreated (a), treated with
uninfected fibroblasts (b), mock adenovirus-infected fibroblasts (c), and IDO adenovirus-infected fibroblasts (d) wounds were excised and sections were strained
with CD31 antibody. (e) Quantitative analysis of capillary-like structures shown in (a). Data are expressed as the mean7SD (n¼ 6).
Figure 6. IDO induces tube formation in HUVECs co-cultured with IDO-
expressing fibroblasts. DiI-labeled HUVECs were co-cultured with either
untreated fibroblast (a and d), mock adenovirus-infected fibroblasts (b and e)
or IDO adenovirus-infected fibroblasts (c and f), and DiI fluorescence (a–c)
and GFP (d–f) fluorescence staining cells were then detected. Original
magnification:  400.
Figure 7. Depletion of tryptophan promotes the formation of capillary-like
structures in HUVECs. DiI-labeled HUVECs were co-cultured with untreated
fibroblasts in the absence (a) or in the presence of 50mg/ml (b) and 100mg/ml (c)
of kynurenine for 20 days. Similarly, DiI-labeled HUVECs were co-cultured
with IDO adenovirus-infected fibroblasts in the absence (d) or in the presence
of 50mg/ml (e) and 100 mg/ml (f) of L-tryptophan for 20 days. The images show
DiI fluorescent labeling cells. Original magnification:  400.
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It has been well established that IDO expression by a
variety of cell types can suppress the immune system in
multiple ways. It has been shown that IDO depletes
tryptophan availability in the microenvironment (Munn
et al., 1999), which damages surrounding activated lympho-
cytes (Li et al., 2004b). In other studies, evidence shows that
IDO promotes the generation of various toxic tryptophan
metabolites such as 3-hydroxyanthranilic acid and quinolinic
acid, which induce activated lymphocyte death (Lee et al.,
2002) and inhibit lymphocyte proliferation (Frumento et al.,
2002; Terness et al., 2002). It has also been demonstrated that
IDO scavenges O2
 (Sun, 1989), which in turn decreases local
inflammatory damage (Daley-Yates et al., 1988). These
unique and synergistic activities of IDO likely collaborate
to inhibit the immune response by the host. The molecular
mechanism of T cell suppression induced by IDO was further
explained in a recent study by Munn et al. (2005),
demonstrating that activation of GCN2 kinase in T cells by
uncharged tRNA mediates T cell proliferative arrest and
anergy induction. They found that T cells with a targeted
disruption of GCN2 were not susceptible to IDO-mediated
suppression of in vitro proliferation. In vivo, proliferation of
GCN2-knockout T cells was not inhibited by IDO-expressing
dendritic cells. GCN2 was originally identified as a regulator
of translation control in response to starvation for one of
many different amino acids (Wek et al., 1989). Uncharged
tRNA that accumulates during amino-acid depletion binds to
a GCN2 regulatory domain homologous to histidyl–tRNA
synthetase enzyme, triggering enhanced eukaryotic initiation
factor-2a kinase activity (Sood et al., 2000). The activation of
eukaryotic initiation factor-2a kinase can provide a signal
transduction pathway linking eukaryotic cellular stress in
response to alterations in the control of gene expression at the
translational level (Clemens, 2001), which in turn results in
cell cycle arrest, lineage-specific differentiation, or apoptosis
(Crosby et al., 2000; Zhang et al., 2002; Rao et al., 2004).
This idea is also supported by our previous study showing that
immune cell damage induced by IDO can be restored with
the addition of tryptophan (Li et al., 2004b). These findings
collectively explain why fewer infiltrated CD3þ T lympho-
cytes were seen in wounds that received IDO genetically
modified fibroblasts on days 14 and 28.
One of the main limitations in using skin substitutes for a
wound coverage is delayed re-vascularization (Sahota et al.,
2004). Young et al. (1996) have suggested that split-thickness
skin grafts survive first by diffusion of nutrients through the
graft (imbibition), then initial vascularization by inosculation,
and finally by neovascularization. Since composite skin
substitutes lack a capillary network, they cannot easily re-
vascularize. Nutrients for these grafts are only supplied by
imbibition and neovascularization. As such, imbibition alone
is unlikely to be sufficient to support the permanent
implantation of skin substitutes until neovascularization is
established (Young et al., 1996). Improvements in skin
substitutes by establishing a capillary-like network either
with the addition of endothelial cells (Black et al., 1998; Supp
et al., 2002; Sahota et al., 2003) or by genetically modifying
skin cells with vascular endothelial growth factor (Supp et al.,
2000, Supp and Boyce, 2002) have been studied. The results of
these studies demonstrated that initiating early neovasculariza-
tion significantly increases graft take. In addition to protecting
xenografted skin cells from immune rejection, IDO also seems
to initiate neovascularization in the early stages as shown in
Figure 5. Direct evidence that IDO promotes angiogenesis was
obtained using our co-culture experiment (Figure 6). Although
understanding the mechanism of how IDO initiates angiogen-
esis in vivo and in vitro requires further study, the fact that
IDO-mediated angiogenesis was reversed with the addition of
tryptophan may indicate that the depletion of tryptophan by an
unknown mechanism stimulates angiogenesis.
In summary, our findings suggest that IDO expression may
function as a local immunosuppressive and neovasculariza-
tion stimulatory factor that protects allo- or xenogeneic
dermal grafts. If true, this will be the first report on the
possibility of developing a non-rejectable skin substitute to be
used for a variety of dermal wound healing disorders.
MATERIALS AND METHODS
Adenoviral vector construction
To construct the adenovirus encoding of a protein of human IDO,
we cloned the PCR product with a full-length protein into a shuttle
vector, which co-expresses a green fluorescent protein (GFP) as a
reporter gene following the manufacturer’s instructions (Q-Biog-
nene, Carlsbad, CA) (Li et al., 2004b). The recombinant adenoviral
plasmids were generated by electroporation of BJ5183 E. coli using
the shuttle vector either with or without IDO. Recombinant
adenoviral plasmids were then purified and transfected to 293 cells
using Fugene-6 transfection reagent (Roche Applied Science, Laval,
QC, Canada). Adenoviral stock were prepared and titered on 293
cells as described previously (Li et al., 2004b).
Fibroblast culture and transfection
Cultures of fibroblasts were established as described previously
(Ghahary et al., 2000). Fibroblasts were grown in Dulbecco’s
modified Eagle’s media with 10% fetal bovine serum and cells from
passages three to seven were used in this study.
Recombinant adenoviruses were used to infect fibroblasts at a
multiplicity of infection of 2000. Free viral particles were removed
from culture medium 30 hours after transfection. Efficiency of
transfection and expression of functional IDO were assessed by
counting the number of GFP-positive cells, using Western blot
against anti-human IDO antibody and measuring the levels of
kynurenine in the conditioned medium as described previously (Li
et al., 2004a, b).
Fibroblast-populated collagen matrices
Type I collagen was isolated and purified from fetal bovine skin by
repeated salt precipitation, as described by Volpin and Veis (1971).
Human fibroblasts were embedded within type I collagen according
to a method modified from Bell et al. (1979). Briefly, fibroblasts
either with or without transfection in a density of 6 105/ml were
mixed with type I collagen (4.29 mg/ml in 0.1% acetic acid),
3Dulbecco’s modified Eagle’s media, chondroitin-6-sulfate (3 mg/
ml in 1Dulbecco’s modified Eagle’s media; Sigma, Oakville, ON,
Canada), and fetal bovine serum at a ratio of 1.5:3.5:3:1:1. After
adjusting the pH to 7.50 with 0.4 N NaOH, the mixture was added
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directly to the culture plate. All dermal substitutes were maintained
in Dulbecco’s modified Eagle’s media with 10% fetal bovine serum
and used for transplantation within 1 week.
Grafting to Sprague–Dawley rats
Procedures on all animal studies were approved by the Health
Sciences Lab Animal Service Animal Welfare Committee of the
University of Alberta, Edmonton, Alberta, Canada. Rats (10 weeks
old) were anesthetized by isoflurane. The dorsal surface of animal
was shaved and cleaned with 70% ethanol. Six full-thickness
excisional wounds were made on the dorsal surface (three wounds
on each side of the midline) using a 6 mm2 punch biopsy tool
(Dormer Laboratories, Mississauga, ON, Canada). Either non-treated,
mock adenovirus infected or IDO transfection fibroblasts were
embedded in a bovine collagen gel and grafted on the wounds. The
wounds were then dressed with gauze impregnated with 3%
Xeroform (Sherwood, St Louis, MO, USA), and the grafted areas
were bandaged. On days 4 and 8, wound closure was measured
and photographed. Animals were killed on days 8, 14, and 28. The
entire wound, including a 2–4 mm margin of unwounded skin, was
carefully excised. Each wound was divided in half. One half
was fixed in 4% paraformaldehyde (Fisher, Pitsburg, PA)
phosphate-buffered saline solution and processed for paraffin
embedding. The other half was snap-frozen by overlaying with
cryomatrix (Thermo Electron Corp., Pittsburgh, PA) with immediate
immersion in a dry ice bath. Tissues were stored at 801C until
analysis.
Histology and immunohistochemistry
Sections were mounted on slides and stained with hematoxylin and
eosin using standard techniques. Wounds were evaluated for the
extent of re-epithelialization, and the granulation tissues were
evaluated based on formation, architecture, and cellularity.
Paraformaldehyde-fixed and paraffin-embedded sections (4 mm)
were deparaffinized and hydrated by incubation in phosphate-
buffered saline for 10 minutes. To retrieve cellular antigens, a
microwave oven heating pretreatment was performed before
blocking with 5% albumin in phosphate-buffered saline solution.
For antibody staining, sections were incubated with either anti-GFP
horseradish peroxidase-conjugated antibody (1:40; Santa Cruz
Biotechnology, Santa Cruz, CA), goat anti-PECAM-1 (CD31, 1:40;
Santa Cruz), or rabbit anti-T cell CD3 peptide (1:200; Sigma) at room
temperature for 1 hour. The second antibody was horseradish
peroxidase-conjugated anti-goat IgG (Sigma) used in CD31 staining
or horseradish peroxidase-conjugated anti-rabbit IgG (Bio-Rad Life
Science, Mississauga, ON, Canada) used in CD3 staining. All second
antibodies were used in a concentration of 1:400. The signal
detection was carried out using 3,30-diaminobenzidine-enhanced
liquid substrate system (Sigma). The slides were counterstained with
hematoxylin for 5 seconds, and then sections were dehydrated,
mounted, and examined under microscopy.
Endothelial cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated by
collagenase digestion (Narumiya et al., 2001). Cells were grown in
an M199 medium (Invitrogen) supplied with 20% fetal bovine serum
and endothelial cell growth supplement (VWR, Mississauga, ON,
Canada) at a final concentration of 10 mg/ml.
In vitro co-culture angiogenesis assay
In vitro angiogenesis assay was assessed through the formation of
capillary-like structures by HUVECs co-cultured with either recom-
binant adenoviral-infected or -uninfected human fibroblasts accord-
ing to a previously reported method (Bishop et al., 1999). To
distinguish the origin of the cells in the tube structure, HUVECs were
trypsinized and labeled by incubation with 40 mg/ml 1,10-dioctade-
cyl-3,3,30,30-tetramethylindocarbocyanin (DiI; Molecular Probes,
Eugene, OR) as described previously (Nehls et al., 1998). Cells
were then thoroughly washed with phosphate-buffered saline. An
equal ratio of HUVECs and fibroblasts (5 105/well) was mixed and
seeded onto a six-well plate. Cells were incubated in M199 supplied
with 20% fetal bovine serum and endothelial cell growth supple-
ment as described above. The medium was replaced every 2 days.
Images of tube structures were taken at day 20 using a spot Jr digital
camera (Diagnostic Instruments, Sterling Heights, MI) attached to a
Leica PBIRB fluorescence microscope (Opti-Tech Scientific Inc.,
Scarborough, ON, Canada).
Kynurenine measurement
The biological activity of IDO was evaluated by measuring the levels
of tryptophan-degraded product, L-kynurenine, present in the condi-
tioned medium derived from IDO and control vector-transfected cells.
The amount of L-kynurenine was measured by a previously
established method (Takikawa et al., 1988). Briefly, proteins in the
conditioned medium were precipitated by trichloroacetic acid, and
after centrifugation, 0.5 ml of supernatant was incubated with an
equal volume of Ehrich’s reagent for 10 minutes at room temperature.
Absorption of the resultant solution was measured at 490 nm by a
spectrophotometer within 2 hours. The values of kynurenine in the
conditioned medium were calculated by a standard curve with the
defined kynurenine (0–100mM) concentration.
Statistical analysis
All data are given as mean7standard deviation. Statistical signifi-
cance was performed using a two-tailed Student’s t-test for unpaired
comparisons between groups. A P-value less than 0.05 is considered
significant.
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